Abstract:Neuregulin 1 gene (NRG1) fusions are oncogenic in various tumor types and represent an emerging potential therapeutic target. In this issue of the Journal of Thoracic Oncology, Nagasaka and Ou1Nagasaka M. Ou S.I. Neuregulin 1 fusion-positive NSCLC.J Thorac Oncol. 2019; 14Google Scholar have highlighted the fact that mainly on the basis of RNA sequencing data, NRG1 fusions are overall rare (0.2%) in the Western population, being seen most frequently in NSCLCs. Given that the population of Asians with lung cancer has a unique mutation spectrum, we retrospectively evaluated the frequency of NRG1 fusions in a total of 22,902 Chinese patients, including 10,966 with NSCLC whose tumor specimen and/or plasma circulating tumor DNA underwent genomic profiling between December 2017 and April 2019 by hybridization capture–based DNA targeted next-generation sequencing of 425 cancer-related genes containing all exons and flanking intronic regions of NRG1 as well as selected exons and introns of previously reported NRG1 fusion partners, including CD74 molecule gene (CD74), SLC3A2 solute carrier family 34 member 2 gene (SLC3A2), syndecan 4 gene (SDC4), and vesicle associated membrane protein 2 gene (VAMP2).2Jonna S. Feldman R.A. Swensen J. et al.Detection of NRG1 gene fusions in solid tumors [e-pub ahead of print]. Clin Cancer Res.https://doi.org/10.1158/1078-0432.CCR-19-016Date accessed: April 15, 2019Google Scholar NRG1 fusions were only detected in patients with NSCLC (Table 1) in our study at a lower incidence of approximately 0.16% (18 of 10,966) than that reported by Jonna et al.2Jonna S. Feldman R.A. Swensen J. et al.Detection of NRG1 gene fusions in solid tumors [e-pub ahead of print]. Clin Cancer Res.https://doi.org/10.1158/1078-0432.CCR-19-016Date accessed: April 15, 2019Google Scholar CD74 represented the most common NRG1 fusion partner in this cohort (Fig. 1). In brief, we identified 11 patients (61%) with CD74-NRG1 fusions, including 10 cases of CD74-NRG1 (C6:N6) (Fig. 2A) and one case of CD74-NRG1 (C8:N2), which had not been previously described (Fig. 2B). We observed two cases that harbored novel fusion variants of SDC4-NRG1 (S2:N2) and SDC4-NRG1 (S2:N6) (Fig. 2C and D), although SDC4-NRG1 (S2:N5) was previously reported in NSCLC by Jones et al.3Jones M.R. Lim H. Shen Y. et al.Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.Ann Oncol. 2017; 28: 3092-3097Abstract Full Text Full Text PDF PubMed Scopus (71) Google Scholar Moreover, a novel fusion event involving integrator complex subunit 9 gene (INTS9)-NRG1 (I1:N7) was identified, although possibly lacking an intact EGF domain. However, fusion partners remained undetermined for the remaining four cases.Table 1Patients' Demographic and Clinical CharacteristicsPatient IDSexHistologic TypeStageSmoking StatusSample TypeFusion PartnerAlterationChr StartChr EndAllele FrequencyTreatment HistoryP-1MLUACIIINonsmokerPlasmaCD74CD74:exon6–NRG1:exon65:1497841038:325577571.32% (PLA)NANRG1:exon5–CD74:exon78:325577195:1497840545.87% (PLA)P-2MLUACINonsmokerFFPESDC4SDC4:exon2–NRG1:exon620:439640528:325603373.37% (FFPE)NANRG1:exon5–SDC4:exon38:3256034220:439640453.4% (FFPE)P-3FLUACIVNAFFPESDC4SDC4:exon2–NRG1:exon220:439636008:324441766.86% (FFPE)Chemotherapy, anti-VEGF antibody (PD)NRG1:exon8–SDC4:exon38:3260943520:439635717.29% (FFPE)P-4MLUACNANAFFPE, plasmaCD74CD74:exon6–NRG1:exon65:1497829218:3247513013.75% (PLA), 38.81% (FFPE)NANRG1:exon5–CD74:exon78:324752465:1497829195.62% (PLA), ND (FFPE)P-5FLUACIVFormer smokerPlasmaCD74CD74: exon6-NRG1:exon65:1497836998:325852920.21% (FFPE)NAP-6FLUACIVNonsmokerFFPECD74CD74:exon6–NRG1:exon65:1497838268:3253021841.92% (FFPE)Surgery, chemotherapy, anti-VEGF antibody (PD)P-7FLUACIIINAFFPE, plasmaCD74CD74:exon6–NRG1:exon65:1497837528:3254000225.93% (FFPE), 18.01% (PLA)NAP-8FLUACNANAFFPECD74CD74:exon6–NRG1:exon65:1497840398:3258533922.15% (FFPE)Chemotherapy, anti-VEGF antibody (PD)P-9MLUACNANAFFPEUnknownIGR (upstream GNPDA2)–NRG1:exon64:448964878:3258535812.8% (FFPE)NAP-10FLUACIVNAFFPE, plasmaCD74CD74:exon6–NRG1:exon65:1497836198:3249256724.39% (FFPE), 6.71% (PLA)SurgeryNRG1:exon5–CD74:exon78:324925575:14978357919.09% (FFPE), 4.86% (PLA)P-14MLUACIVNAFFPEUnknownIGR (downstream POTEA)–NRG1:exon18:435856468:314977162.3% (FFPE)NAP-15FLUACNANAFFPEUnknownIGR (downstream TRPS1)–NRG1:exon68:1163457108:3250550817.81% (FFPE)NAP-17FLUACNANAFFPECD74CD74:exon6–NRG1:exon65:1497832658:3254903626.79% (FFPE)NAP-19FLUACNANAFFPECD74NRG1:exon1–CD74:exon88:322832705:14978174712.3% (FFPE)SurgeryCD74:exon8–NRG1:exon65:1497817468:3249742710.78% (FFPE)P-20FLUACNANAFFPEINTS9INTS9:exon1–NRG1:exon78:287247238:3259927420.51% (FFPE)NAP-21MLUACNANAFFPECD74CD74:exon6–NRG1:exon65:1497823248:3255883012.9% (FFPE)NAP-22FLUACNANAFFPEUnknownIGR (upstream EXTL3)–NRG1:exon28:285075988:3240645626.09% (FFPE)NAP-26FLUACIIINAFFPECD74CD74:exon6–NRG1:exon65:1497829868:3257693428.95% (FFPE)NACD74, Cluseter of differentiation 74; Chr, chromosome; EXTL3, exostosin like glycosyltransferase 3 gene; F, female; FFPE, formalin-fixed, paraffin-embedded; GNPDA2, glucosamine-6-phosphate diaminase 2 gene; ID, identifier; IGR, intergenic region; INTS9, integrator complex unit gene; LUAC, lung adenocarcinoma; M, male; NA, not available; ND, not detected; NRG1, neuregulin 1 gene; P, patient; PD, progressive disease; PLA, plasma; POOTEA, POTE ankyrin domain family member A gene; SDC4, syndecan 4 gene; TRPS1, transcriptional repressor GATA binding 1 gene; VEGF, vascular endothelial growth factor. Open table in a new tab Figure 2Visualization of neuregulin 1 gene (NRG1) fusions, including fusion partners using the Integrated Genomics Viewer browser (Broad Institute). The Integrated Genomics Viewer screenshots display the reads from next-generation sequencing and reveal NRG1 fusions of CD74 molecule gene (CD74)-NRG1 (C6:N6) (A), CD74-NRG1 (C8:N6) (B), syndecan 4 gene (SDC4)-NRG1 (S2:N2) (C), SDC4-NRG1 (S2:N6) (D), and integrator complex subunit 9 (INTS9)-NRG1 (I1:N7) (E). P, patient.View Large Image Figure ViewerDownload Hi-res image Download (PPT) CD74, Cluseter of differentiation 74; Chr, chromosome; EXTL3, exostosin like glycosyltransferase 3 gene; F, female; FFPE, formalin-fixed, paraffin-embedded; GNPDA2, glucosamine-6-phosphate diaminase 2 gene; ID, identifier; IGR, intergenic region; INTS9, integrator complex unit gene; LUAC, lung adenocarcinoma; M, male; NA, not available; ND, not detected; NRG1, neuregulin 1 gene; P, patient; PD, progressive disease; PLA, plasma; POOTEA, POTE ankyrin domain family member A gene; SDC4, syndecan 4 gene; TRPS1, transcriptional repressor GATA binding 1 gene; VEGF, vascular endothelial growth factor. NRG1 fusions were more frequently detected in females (in 67% [12 of 18]), but whether smoking status correlated with the occurrence of NRG1 fusion remained unclear owing to the unavailability of most patients’ smoking history. Furthermore, concomitant tumor protein p 53 gene (TP53) alterations were most frequently seen in these patients (in 83% [15 of 18]). Twelve out of 13 cases (92%) harboring potentially functional fusions had no other dominant oncogenic mutations, except for one CD74-NRG1 (C6:N6) case with a concurrent KRAS G12D mutation. However, four out of five cases (80%) either lacking an intact EGF domain or involving unknown fusion partners carried concurrent driver mutations, including EGFR L858R and KRAS G13D. In summary, we report the occurrence and distribution of NRG1 fusions in a large Chinese NSCLC population. Rare NRG1 fusions could possibly be missed owing to the limitation of hybridization capture–based DNA sequencing method for targeting the deep intronic regions of NRG1 involved in fusions. Patients’ medical records showed that three patients progressed shortly after beginning chemotherapy and anti–vascular endothelial growth factor receptor therapy, whereas the remainder (83% [15 of 18]) were systemic treatment–naive. Nagasaka et al.1Nagasaka M. Ou S.I. Neuregulin 1 fusion-positive NSCLC.J Thorac Oncol. 2019; 14Google Scholar described mixed success in treating with patients with NRG1 fusion with anti–erb-b2 receptor tyrosine kinase 2 kinase agents, including afatinib and anti–erb-b2 receptor tyrosine kinase 3 monoclonal antibodies such as GSK28493304Drilon A. Somwar R. Mangatt B.P. et al.Response to ERBB3-directed targeted therapy in NRG1-rearranged cancers.Cancer Discov. 2018; 8: 686-695Crossref PubMed Scopus (103) Google Scholar and lumretuzumab.5Meulendijks D. Jacob W. Martinez-Garcia M. et al.First-in-human phase I study of lumretuzumab, a glycoengineered humanized anti-HER3 monoclonal antibody, in patients with metastatic or advanced HER3-positive solid tumors.Clin Cancer Res. 2016; 22: 877-885Crossref PubMed Scopus (49) Google Scholar In light of this fact, reminiscent of targeting NTRK fusions, a tumor-agnostic treatment strategy should also be considered for the therapeutic management of patients with NRG1 fusion in the immediate future. This work was supported by funds provided to Dr. Lu by the National Key R&D Program of China (grant 2016YFC1303300), the National Natural Science Foundation of China (grant 81672272), Shanghai Municipal Science and Technology Commission Research Project (grant 17431906103), Shanghai Chest Hospital Project of Collaborative Innovation (grant YJXT20190105), and the Clinical Research Plan of SHDC (grant 16CR3005A).

A Multicenter Study of NRG1 Fusions in Chinese Non-Small Cell Lung Cancer Patients and Response to Afatinib Using Next Generation Sequencing

Real-World Large-Scale Study Of Erbb2 Gene Fusions And Its Response To Afatinib In Chinese Non-Small Cell Lung Cancer (Nsclc): A Multicenter Study.

[Afatinib Treatment for Advanced Mixed Non-small Cell Lung Cancer with CRISPLD2-NRG1 Fusion: A Case Report and Literature Review]

Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions

Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry.

Efficacy of Pemetrexed-Based Chemotherapy in Advanced NSCLC Chinese Patients with NRG1 Fusions by TNA Sequencing: A Multicenter Study

Genomic Characterization and Outcome Evaluation of Kinome Fusions in a Large Non-Small Cell Lung Cancer Population.

Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population.

P2.03-09 the Real World of NTRK Fusion Data in the Chinese Lung Cancer Populations: A Multicenter Study

Chinese advanced fusion-dependent lung cancer patients: Molecular spectrum and treatment options using next generation sequencing—A multicenter study (Yangtze River Delta Lung Cancer Cooperation Group-001).

Expert Consensus on the Diagnosis and Treatment of NRG1/2 Gene Fusion Solid Tumors

Prevalence of EGFR Gene Fusions in a Large Cohort of Chinese Patients with Non-Small Cell Lung Cancer (NSCLC).

Incidence of FGFR-TACC Gene Fusions in Chinese Non-Small Cell Lung Cancer (NSCLC): A Multicenter Study.

Distribution of NRG1 Gene Fusions in a Large Population of Chinese Patients with NSCLC

Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib

ALK fusion typing and response to crizotinib in ALK+ lung cancer-naive patients.

Analysis on the pathogenesis and treatment progress of NRG1 fusion-positive non-small cell lung cancer

A Novel KIF5B-EGFR Fusion Variant in Non-Small-Cell Lung Cancer and Response to Afatinib: A Case Report

P1.13-08 Distribution, Differences in Clinical Characteristics and Resistance Mechanism of ALK Variants in Chinese Lung Cancer Patients

A case of multiple primary lung adenocarcinoma with a CD74‐NRG1 fusion protein and HER2 mutation benefit from combined target therapy

EP1.14-45 ROS1-ADGRG6: A Novel ROS1 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Crizotinib